Terminated PHASE2 INTERVENTIONAL 1-arm NCT00413478

5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

Phase II Study of 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia

Sponsor: Celgene Corporation

Conditions Chronic Lymphocytic Leukemia Leukemia

Updated 8 times since 2017 Last updated: Jun 26, 2015 Started: Sep 30, 2006 Primary completion: Nov 30, 2014 Completion: Nov 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow accrual.

Other terminated trials from Celgene Corporation

More terminations from Celgene Corporation

Other Chronic Lymphocytic Leukemia trials with similar outcome

Browse all Chronic Lymphocytic Leukemia trials

This PHASE2 trial investigates Chronic Lymphocytic Leukemia and Leukemia and is currently terminated or withdrawn. Celgene Corporation leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2
Dec 2021 — Dec 2022 [monthly]

Terminated PHASE2

▶ Show 3 earlier versions

Jan 2021 — Dec 2021 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation
M.D. Anderson Cancer Center

Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States